查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869957

抗精神病药物市场规模、份额和趋势分析报告：按疾病、药物、治疗类别、分销管道、地区和细分市场预测（2025-2033 年）

Antipsychotic Drugs Market Size, Share & Trends Analysis Report By Disease (Schizophrenia, Bipolar Disorder), By Drug, By Therapeutic Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 110 Pages | 商品交期: 2-10个工作天内

价格

抗精神病药物市场摘要

2024年全球抗精神病药物市场规模估计为175.3亿美元，预计2033年将达到322.4亿美元。

预计2025年至2033年间，该市场将以6.1%的复合年增长率成长。市场扩张主要归因于精神疾病盛行率的上升、公众意识的提高以及技术创新。政府支持、保险覆盖范围的扩大以及学名药的广泛普及，进一步提高了药物的可及性，尤其是在新兴市场。

抗精神病药物（也称为阻断剂）常用于缓解精神病相关症状。抗精神病药物能有效减轻和控制多种症状，包括妄想和幻听（听到声音）。其作用机制是透过抑制大脑中多巴胺和其他神经传导物质的活性。目前市面上已有第一代和第二代抗精神病药物。

精神病性障碍盛行率的不断上升预计将推动抗精神病药物行业的需求。思觉失调症在男性中的盛行率始终高于女性，随着各地预期寿命的延长，思觉失调症的整体负担预计将进一步加重。人口老化也是支撑需求的因素之一，因为诸如失智症相关精神病等疾病变得越来越常见。新型製剂和具有全新作用机制的药物获得监管部门核准，克服了传统疗法的局限性，进一步促进了市场成长。

科技进步与研发的推动，促使新型、更有效的抗精神病药物不断涌现。製药公司正大力投资研发副作用更少、疗效更佳、患者依从性更高的药物。 2025年9月，H. Lundbeck和Otsuka Holdings Co., Ltd.收到了美国食品药物管理局（FDA）的完整回覆函（CRL），该函针对的是Rexulty（Brexpiprazole）和舍曲林联合治疗接受成人创伤后压力症候群（PTSD）的补充新药认证申请（sNDA）。

Eisai的阿兹海默症治疗核准Rekemvi于2023年1月核准。神经系统疾病先进治疗方案的引入导致全球患者使用抗精神病药物的情况增加。

目录

第一章调查方法和范围

第二章执行摘要

第三章 抗精神病药物市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 抗精神病药物市场分析工具
    • 产业分析—波特五力分析
    • PESTEL 分析

第四章：抗精神病药物市场：依疾病区分的估算与趋势分析

  • 疾病细分仪表板
  • 抗精神病药物市场：按疾病分類的变化分析
  • 全球抗精神病药物市场规模及趋势分析（依疾病分类，2021-2033 年）
    • 思觉失调症
    • 躁郁症
    • 单相忧郁症
    • 失智
    • 其他的

第五章：抗精神病药物市场：药物具体估算与趋势分析

  • 药品细分仪表板
  • 抗精神病药物市场：按药物分类的波动分析
  • 全球抗精神病药物市场规模及趋势分析（按药物分类，2021-2033 年）
    • Risperidone
    • Quetiapine
    • Olanzapine
    • Aripiprazole
    • Brexpiprazole
    • 棕榈酸帕利哌酮
    • 其他的

第六章：抗精神病药物市场：依治疗层级的估算与趋势分析

  • 治疗层级细分仪表板
  • 抗精神病药物市场：依治疗类别分析变化
  • 全球抗精神病药物市场规模及趋势分析（按治疗层级，2021-2033 年）
    • 第一代
    • 第二代
    • 第三代

第七章：抗精神病药物市场：按分销管道分類的估算和趋势分析

  • 分销通路细分仪表板
  • 抗精神病药物市场：按分销管道分析波动情况
  • 全球抗精神病药物市场规模及趋势分析（按分销管道划分，2021-2033 年）
    • 医院药房
    • 零售药房
    • 网路药房

第八章：抗精神病药物市场：区域估算与趋势分析

  • 区域市场概览
  • 2024 年及 2033 年区域市占率分析
  • 区域市场：主要结论
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第九章 竞争情势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商概况
  • 公司简介
    • H. Lundbeck A/S
    • Otsuka Pharmaceutical Co., Ltd.
    • Janssen Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • AbbVie, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Dr Reddy's Laboratories Ltd.
    • Sumitomo Pharma Co., Ltd.
    • Alkermes
    • Bristol-Myers Squibb Company
Product Code: GVR-1-68038-408-6

Antipsychotic Drugs Market Summary

The global antipsychotic drugs market size was estimated at USD 17.53 billion in 2024 and is projected to reach USD 32.24 billion by 2033, growing at a CAGR of 6.1% from 2025 to 2033. The market is expanding due to the increasing prevalence of mental health disorders, greater awareness, and innovations. Government support, insurance coverage, and the availability of generics are further driving accessibility, especially in emerging markets.

Antipsychotic medications, also known as neuroleptics, are commonly employed to alleviate symptoms linked to psychosis. Antipsychotic medications can effectively decrease and manage various symptoms, such as paranoia and auditory hallucinations, including delusions and hearing voices. Antipsychotic medications work by inhibiting the activity of dopamine and other neurotransmitters in the brain. First and second-generation antipsychotic medications are currently available in the market.

The increasing prevalence of psychotic disorders is expected to drive the demand in the antipsychotic drugs industry. The Schizophrenia burden consistently affects men more than women, and as life expectancy improves regionally, the overall burden of Schizophrenia is expected to grow further. Aging populations also support demand, as conditions such as dementia-related psychosis become more prevalent. Market growth has been reinforced by regulatory approvals of new formulations and novel mechanisms of action, which address limitations of older therapies.

Advancements in technology and research in drug development have also resulted in the creation of newer and more efficient Antipsychotic drugs. Pharmaceutical companies are investing significantly in researching and developing medications with fewer side effects, higher effectiveness, and enhanced patient adherence. In September 2025, H. Lundbeck A/S and Otsuka Holdings Co., Ltd received a Complete Response Letter (CRL) from the FDA for a supplemental New Drug Application (NDA) for REXULTI (brexpiprazole) in combination with sertraline for treating adults with PTSD.

In January 2023, Eisai Co., Ltd. obtained FDA approval for Leqembi through the Accelerated Approval Pathway for Alzheimer's disease treatment. The introduction of advanced pharmaceutical choices for neurological disorders is increasing the use of antipsychotic drugs among patients worldwide.

Global Antipsychotic Drugs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global antipsychotic drugs market report based on disease, drug, therapeutic class, distribution channel, and region:

  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Schizophrenia
  • Bipolar Disorder
  • Unipolar Depression
  • Dementia
  • Others
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Risperidone
  • Quetiapine
  • Olanzapine
  • Aripiprazole
  • Brexpiprazole
  • Paliperidone Palmitate
  • Others
  • Therapeutic Class Outlook (Revenue, USD Million, 2021 - 2033)
  • First Generation
  • Second Generation
  • Third Generation
  • Distribution Channel Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Drug
    • 1.2.3. Therapeutic class
    • 1.2.4. Distribution channel
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Drug outlook
    • 2.2.3. Therapeutic class
    • 2.2.4. Distribution Channel
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antipsychotic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Antipsychotic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antipsychotic Drugs Market: Disease Estimates & Trend Analysis

  • 4.1. Disease Segment Dashboard
  • 4.2. Antipsychotic Drugs Market: Disease Movement Analysis
  • 4.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
    • 4.3.1. Schizophrenia
      • 4.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.2. Bipolar Disorder
      • 4.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.3. Unipolar Depression
      • 4.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.4. Dementia
      • 4.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.3.5. Others
      • 4.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Antipsychotic Drugs Market: Drugs Estimates & Trend Analysis

  • 5.1. Drugs Segment Dashboard
  • 5.2. Antipsychotic Drugs Market: Drug Movement Analysis
  • 5.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Drugs, 2021 to 2033 (USD Million)
    • 5.3.1. Risperidone
      • 5.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.2. Quetiapine
      • 5.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.3. Olanzapine
      • 5.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.4. Aripiprazole
      • 5.3.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.5. Brexpiprazole
      • 5.3.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.6. Paliperidone Palmitate
      • 5.3.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.3.7. Others
      • 5.3.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Antipsychotic Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 6.1. Therapeutic Class Segment Dashboard
  • 6.2. Antipsychotic Drugs Market: Therapeutic Class Movement Analysis
  • 6.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Therapeutic Class, 2021 to 2033 (USD Million)
    • 6.3.1. First Generation
      • 6.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.2. Second Generation
      • 6.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.3.3. Third Generation
      • 6.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Antipsychotic Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Segment Dashboard
  • 7.2. Antipsychotic Drugs Market: Distribution Channel Movement Analysis
  • 7.3. Global Antipsychotic Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
    • 7.3.1. Hospital Pharmacies
      • 7.3.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.2. Retail Pharmacies
      • 7.3.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.3.3. Online Pharmacies
      • 7.3.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Antipsychotic Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Dashboard
  • 8.2. Regional Market Share Analysis, 2024 & 2033
  • 8.3. Continuous bioprocessing market by Region: Key Takeaways
  • 8.4. North America
    • 8.4.1. U.S.
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.2. Canada
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.4.3. Mexico
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.2. Germany
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.3. France
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.4. Italy
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.5. Spain
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.6. Denmark
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.7. Sweden
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Regulatory framework/ reimbursement structure
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.8. Norway
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Regulatory framework/ reimbursement structure
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.3. India
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/ reimbursement structure
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.4. Australia
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/ reimbursement structure
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/ reimbursement structure
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.6.6. Thailand
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/ reimbursement structure
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.7.2. Argentina
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework/ reimbursement structure
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/ reimbursement structure
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.3. UAE
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/ reimbursement structure
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.8.4. Kuwait
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Regulatory framework/ reimbursement structure
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. Key company heat map analysis, 2024
  • 9.4. Company Profiles
    • 9.4.1. H. Lundbeck A/S
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Otsuka Pharmaceutical Co., Ltd.
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. Janssen Pharmaceuticals, Inc.
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. Eli Lilly and Company
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. AbbVie, Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. Teva Pharmaceutical Industries Ltd.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Dr Reddy's Laboratories Ltd.
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. Sumitomo Pharma Co., Ltd.
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Alkermes
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global antipsychotic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 4 Global antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 5 Global antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 6 Global antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 9 North America antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 10 North America antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 11 North America antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 12 U.S. antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 13 U.S. antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 14 U.S. antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 15 U.S. antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 16 Canada antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 17 Canada antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 18 Canada antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 19 Mexico antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 20 Mexico antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 21 Mexico surgical ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 22 Mexico antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 23 Europe antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 24 Europe antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 25 Europe antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 26 Europe antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 27 Europe antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 UK antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 29 UK antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 30 UK antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 31 UK antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Germany antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 33 Germany antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 34 Germany antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 35 Germany antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 France antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 37 France antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 38 France antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 39 France antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 40 Italy antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 41 Italy antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 42 Italy antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 43 Italy antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 44 Spain antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 45 Spain antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 46 Spain antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 47 Spain antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Denmark antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 49 Denmark antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 50 Denmark antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 51 Denmark antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Sweden antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 53 Sweden antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 54 Sweden antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 55 Sweden antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Norway antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 57 Norway antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 58 Norway antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 59 Norway antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 60 Asia Pacific antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Japan antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 66 Japan antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 67 Japan antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 68 Japan antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 69 China antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 70 China antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 71 China antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 72 China antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 73 India antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 74 India antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 75 India antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 76 India antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Australia antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 78 Australia antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 79 Australia antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 80 Australia antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 81 South Korea antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 82 South Korea antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 83 South Korea antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 84 South Korea antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 85 Thailand antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 86 Thailand antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 87 Thailand antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 88 Thailand antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 89 Latin America antipsychotic drugs market, by country, 2021 - 2033 (USD Million)
  • Table 90 Latin America antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 91 Latin America surgical ablation market, by drug, 2021 - 2033 (USD Million)
  • Table 92 Latin America laparoscopic ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 93 Latin America percutaneous ablation market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 94 Brazil Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 95 Brazil Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 96 Brazil surgical ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 97 Brazil antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 98 Argentina Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 99 Argentina Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 100 Argentina surgical ablation market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 101 Argentina antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 102 MEA Antipsychotic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 103 MEA Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 104 MEA Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 105 MEA Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 106 MEA antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 107 South Africa Antipsychotic drugs market, by Disease, 2021 - 2033 (USD Million)
  • Table 108 South Africa Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 109 South Africa Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 110 South Africa antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 111 Saudi Arabia Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 115 UAE Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 116 UAE Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 117 UAE Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 118 UAE antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 119 Kuwait Antipsychotic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 120 Kuwait Antipsychotic drugs market, by drug, 2021 - 2033 (USD Million)
  • Table 121 Kuwait Antipsychotic drugs market, by therapeutic class, 2021 - 2033 (USD Million)
  • Table 122 Kuwait antipsychotic drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Antipsychotic drugs market: market outlook
  • Fig. 10 Antipsychotic drugs: Competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Antipsychotic drugs market driver impact
  • Fig. 16 Antipsychotic drugs market restraint impact
  • Fig. 17 Antipsychotic drugs market strategic initiatives analysis
  • Fig. 18 Antipsychotic drugs market: disease movement analysis
  • Fig. 19 Antipsychotic drugs market: disease outlook and key takeaways
  • Fig. 20 Schizophrenia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Bipolar disorder market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Unipolar depression market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 Dementia market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 Other market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Antipsychotic drugs market: Drug movement Analysis
  • Fig. 26 Antipsychotic drugs market: Drug outlook and key takeaways
  • Fig. 27 Schizophrenia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Bipolar disorder market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 29 Unipolar depression market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 30 Dementia market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 31 Other market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 32 Antipsychotic drugs market: Therapeutic class movement analysis
  • Fig. 33 Antipsychotic drugs market: Therapeutic Class outlook and key takeaways
  • Fig. 34 First-generation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Second-generation market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 36 Third-generation market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Antipsychotic drugs market: Distribution channel movement analysis
  • Fig. 38 Antipsychotic drugs market: Distribution channel outlook and key takeaways
  • Fig. 39 Hospital pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Retail pharmacies market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 41 Online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Global antipsychotic drugs market: Regional movement analysis
  • Fig. 43 Global antipsychotic drugs market: Regional outlook and key takeaways
  • Fig. 44 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)